Skip to main content
. Author manuscript; available in PMC: 2016 Nov 1.
Published in final edited form as: Arterioscler Thromb Vasc Biol. 2015 Sep 17;35(11):2366–2373. doi: 10.1161/ATVBAHA.115.305796

Figure 5. PTIO reduces aortic endothelial DHFR expression and BH4 content via proteasomal degradation ex vivo.

Figure 5

(A) Western blot analysis showed reduced DHFR expression in PTIO- (150µM) treated aortas, which could be blocked by MG132 (1µM, 6h) supplementation. (B) Representative immunofluorescence staining of DHFR (red) and endothelium marker CD31 (green) of ex vivo cultured aortas. (C) PTIO (150µM) reduced endothelial DHFR expression, while MG132 (1µM, 6h) reversed the effect. (D) Representative immunofluorescence staining of GTPCH (red) and endothelium marker CD31 (green) of ex vivo cultured aortas. (E) PTIO (150µM) had no significant effect on endothelial GTPCH expression. (F) PTIO (150µM) reduced BH4 content, which could be reversed by addition of MG132 (1µM, 6h) in aortas ex vivo. (n=4 for each group; *p<0.05 vs. control; #p<0.05 vs. PTIO)